April Boll Iowa State University. Leo L. Timms Iowa State University. Recommended Citation

Similar documents
THIS ARTICLE IS SPONSORED BY THE MINNESOTA DAIRY HEALTH CONFERENCE.

Milk Quality Management Protocol: Fresh Cows

Using SCC to Evaluate Subclinical Mastitis Cows

Using DHIA and bacteriology to investigate herd milk quality problems.

Controlling Contagious Mastitis

2012 Indiana Regional Dairy Meetings. Purdue University College of Veterinary Medicine Dr. Jon Townsend Dairy Production Medicine

Walter M. Guterbock, DVM, MS Veterinary Medicine Teaching and Research Center University of California, Davis

On-farm milk culture training workshop. Christina Petersson-Wolfe Department of Dairy Science Virginia Tech

Milk Quality Evaluation Tools for Dairy Farmers

Dr. Michelle Arnold, DVM DABVP (Food Animal) Ruminant Extension Veterinarian University of Kentucky Veterinary Diagnostic Laboratory

Strep. ag.-infected Dairy Cows

Mastitis: Background, Management and Control

The use of on-farm culture systems for making treatment decisions

MASTITIS CASE MANAGEMENT

How to Decrease the Use of Antibiotics in Udder Health Management

DeLaval Cell Counter ICC User Strategies Guide

Presented at Central Veterinary Conference, Kansas City, MO, August 2013; Copyright 2013, P.L Ruegg, all rights reserved

Decision tree analysis of treatment strategies for mild and moderate cases of clinical mastitis occurring in early lactation

Mastitis MANAGING SOMATIC CELLS COUNTS IN. Somatic Cell Count Are Affected by. Somatic Cells are NOT Affected by:

On- farm milk culture training workshop

Field Efficacy of J-VAC Vaccines in the Prevention of Clinical Coliform Mastitis in Dairy Cattle

Last 2-3 months of lactation

Outline MILK QUALITY AND MASTITIS TREATMENTS ON ORGANIC 2/6/12

MASTITIS DNA SCREENING

Summary. Table 1. Estimated infection prevalence and losses in milk production associated with elevated bulk tank somatic cell counts.

Quality Milk on Pasture Based Dairy Farms. Scott E. Poock, DVM University of Missouri Clinical Assistant Professor DABVP Beef and Dairy Cattle

Selective Antibiotic Treatment for Dairy Cow Mastitis 1

Interpretation and Use of Laboratory Culture Results and the Characteristics of Various Mastitis Pathogens

Interpretation and Use of Laboratory Culture Results and the Characteristics of Various Mastitis Pathogens

Emerging Mastitis Threats on the Dairy Pamela Ruegg, DVM, MPVM Dept. of Dairy Science

Dairy/Milk Testing Report Detecting Elevated Levels of Bacteria in Milk-On-Site Direct- From-The-Cow Within Minutes as Indicator of Mastitis

Institut for Produktionsdyr og Heste

, Pamela L. Ruegg

Premiums, Production and Pails of Discarded Milk How Much Money Does Mastitis Cost You? Pamela Ruegg, DVM, MPVM University of Wisconsin, Madison

Milk quality & mastitis - troubleshooting, control program

MILK QUALITY PROGRAMS FOR TRANSITION COWS AND HEIFERS. Leo Timms Iowa State University, Ames IA

Interpretation of Bulk Tank Milk Results

A PRACTISING VETS APPROACH TO THE HIGH CELL COUNT HERD

29/11/2017. Best Milking Practices. Greg Strait- Fulton County Extension Amber Yutzy- Huntingdon County Extension

Practical Strategies for Treating Mastitis Pamela L. Ruegg, DVM, MPVM University of Wisconsin, Madison

1/1/ K BEAT IT!

Trouble-Shooting a Mastitis Problem Herd 1

Selective Dry Cow Therapy

Northern NY Agricultural Development Program 2016 Project Report

S. P. Oliver, R. A. Almeida, B. E. Gillespie, S. J. Ivey, H. Moorehead, P. Lunn, H. H. Dowlen, D. L. Johnson, and K. C. Lamar

The mastitis situation in Canada where do you stand?

Minna Koivula & Esa Mäntysaari, MTT Agrifood Research Finland, Animal Production Research, Jokioinen, Finland

Prototheca Mastitis in Dairy Cows

Mastitis and On-Farm Milk Cultures - A Field Study - Part 1

Prevalence of sub clinical mastitis in small holder dairy farms in Selale, North Shewa Zone, Central Ethiopia

Association between teat skin colonization and intramammary infections with Staphylococcus aureus and Streptococcus agalactiae

Influence of Management Techniques on the Levels of Mastitis in an Organic Dairy Herd Mastitis management in organic herd

F-MC-2: Dealing with Streptococcus agalactiae Mastitis

Effect of omitting post-milking teat disinfection on the mastitis infection rate of dairy cows over a full lactation

Options for Handling Mastitis during Lactation in Modern Dairy Farms

LOOKING FOR PROFITS IN MILK QUALITY

A Partial Budget Model to Estimate Economic Benefits of Lactational Treatment of Subclinical Staphylococcus aureus Mastitis

CLINICAL MASTITIS PERCEPTIONS OF KANSAS DAIRY PRODUCERS. J.R. Roberson 1

Subclinical mastitis in small ruminants: prevalence, comparative aspects and prevention

Evaluation of intervention strategies for subclinical and clinical mastitis

Mastitis Reminders and Resources LAURA SIEGLE EXTENSION AGENT VIRGINIA COOPERATIVE EXTENSION AMELIA COUNTY

PREVALENCE OF SUBCLINICAL MASTITIS AND ANTIBIOTIC RESISTANT BACTERIA IN THREE SELECTED CATTLE, FARMS IN SERDANG, SELANGORAND KLUANG, JOHOR

Guideline on the conduct of efficacy studies for intramammary products for use in cattle

Mastitis in ewes: towards development of a prevention and treatment plan

The Bimeda Guide to Selective Dry Cow Therapy

Mastitis cows and immunization

Management Practices and Intramammary Infections: New Ideas for an Old Problem

BIOSECURITY ON DAIRIES... ARE WE DOING ENOUGH?

Selective Dry Cow Therapy

Vaccination as a Tool to Reduce Mastitis and Improve Milk Quality in Dairy Goats. F.M. Kautz, S. C. Nickerson, and L. O. Ely.

MASTITIS, ANTIBIOTICS, AND RESISTANCE: A ROUND- TABLE DISCUSSION WITH DR. ROB TREMBLAY

Innovation in Mastitis Treatment

ENVIRACOR J-5 aids in the control of clinical signs associated with Escherichia coli (E. coli) mastitis

Update on Staphylococcus aureus Mastitis. John R. Middleton College of Veterinary Medicine, University of Missouri, Columbia

Prevalence and Drug Resistance Patterns of Staphylococcus Aureus in Lactating Dairy Cow s Milk in Wolayta Sodo, Ethiopia

Working with your vet to improve your dairy

1. Introduction EVALUATION OF A MASTITIS CONTROL PROGRAMME ADOPTED IN SMALL DAIRIES IN THE DISTRICT OF COLOMBO

NEW ZEALAND DAIRY INDUSTRY AND COLOSTRUM

Finnzymes Oy. PathoProof Mastitis PCR Assay. Real time PCR based mastitis testing in milk monitoring programs

Quad Plate User s Manual

Use of a staphylococcal vaccine to reduce prevalence of mastitis and lower somatic cell counts in a registered Saanen dairy goat herd

New York State Cattle Health Assurance Program Fact Sheet Udder Health Herd Goals

MILK COMPOSITIONAL CHANGES DURING MASTITIS

Proper Dry-Off Procedures to Prevent New Infections and Cure Existing Cases of Mastitis. Stephen C. Nickerson University of Georgia

Bovine Mastitis Products for Microbiological Analysis

University of Missouri Extension Using the California Mastitis Test

Mastitis Module Risk Assessment Guide by Pathogen. Streptococcus agalactiae

TREATMENT DECISIONS FOR MILD AND MODERATE CASES OF CLINICAL MASTITIS. Carolina Pinzón-Sánchez

Estimating the Cost of Disease in The Vital 90 TM Days

Sources of Different Mastitis Organisms and Their Control

Mastitis in Dairy. Cattle. Oregon State System of Higher Education Agricultural Experiment Station Oregon State College JOHN 0.

Milking Management II - Mastitis 1

Mastitis control in bred heifers: Use of dry cow therapy and teat sealant for curing existing intramammary infections and preventing new ones

MASTITIS. Therefore, mastitis is an inflammation of the mammary gland.

Guideline on the conduct of efficacy studies for intramammary products for use in cattle

Guideline on the conduct of efficacy studies for intramammary products for use in cattle

Interpretation of results from milk samples tested for mastitis bacteria with Mastit 4 qpcr test from DNA Diagnostic

Economics of mastitis. Kirsten Huijps and Henk Hogeveen

TEAT DIP- POST DIP- PRE DIP- STRIPING

Veterinaria.com.pt 2009; Vol. 1 Nº 1: e13 (publicação inicial em Julho de 2008) Disponível em

Transcription:

AS 652 ASL R2102 2006 Use of the California Mastitis Test and an On-Farm Culture System for Strategic Identification and Treatment of Fresh Cow Subclinical Intramammary Infections and Treatment of Clinical Mastitis April Boll Iowa State University Leo L. Timms Iowa State University Recommended Citation Boll, April and Timms, Leo L. (2006) "Use of the California Mastitis Test and an On-Farm Culture System for Strategic Identification and Treatment of Fresh Cow Subclinical Intramammary Infections and Treatment of Clinical Mastitis," Animal Industry Report: AS 652, ASL R2102. Available at: http://lib.dr.iastate.edu/ans_air/vol652/iss1/35 This Dairy is brought to you for free and open access by the Animal Science Research Reports at Iowa State University Digital Repository. It has been accepted for inclusion in Animal Industry Report by an authorized editor of Iowa State University Digital Repository. For more information, please contact digirep@iastate.edu.

Use of the California Mastitis Test and an On-Farm Culture System for Strategic Identification and Treatment of Fresh Cow Subclinical Intramammary Infections and Treatment of Clinical Mastitis A.S. Leaflet R2102 April Boll, freshman veterinary student; Leo Timms, associate professor of animal science Summary and Implications The purpose of this research was to evaluate the use of an on-farm culture system in conjunction with the California Mastitis Test for the strategic treatment of subclinical mastitis in fresh cows and clinical mastitis. CMT showed high NPV indicating it was very effective in determining uninfected quarters. However, PPV were low resulting in many CMT+ quarters being uninfected; thus many uninfected quarters being treated also. Cure rates in both the fresh and clinical animals did not change when treatment was delayed for twenty-four hours while waiting for culture results This would indicate that waiting for culture results before instituting treatment does not affect treatment success. The on-farm culture system, in conjunction with the CMT, dramatically reduced the number of animals treated with antimicrobials as compared to basing treatment The purpose of this research is to evaluate the use of an onfarm culture system in conjunction with the California Mastitis Test for the strategic treatment of subclinical mastitis in fresh cows and clinical mastitis. A cost-benefit analysis will also be used to determine the economic feasibility of an on-farm culture system for commercial use. Materials and Methods Fresh Cow Protocol (Figure 1): Approximately 75 animals calved between June and August at the Iowa State University Dairy Farm. Within twenty-four hours of calving, all fresh animals had a CMT performed on milk from all individual quarters. Aseptic quarter samples were also taken from all quarters and cultured for mastitis organisms using National Mastitis Council procedures. Milk from each quarter was initially swabbed on both blood and MacConkey agar plates and incubated at 37 C for twentyfour hours at the dairy. Organisms that showed growth on both the blood and MacConkey agar were assumed to be gram negative, while organisms that grew only on the blood agar were assumed to be gram positive. Plates showing growth were submitted to the clinical microbiology lab at the Iowa State University College of Veterinary Medicine for identification and antibiotic susceptibility testing. Quarters and cows testing negative on the CMT received no other treatments. Cows that were CMT positive were randomly assigned to one of two treatment groups blocked by first and other lactations. The first group (control) was immediately treated with the antimicrobial Pirlimycin hydrocholoride (Pirsue, Pfizer, Inc) for two total treatments twenty-four hours apart in all CMT positive quarters. The second group (wait) was not treated until culture results became available twenty-four hours post CMT. Quarters with gram negative organisms or showing no growth were not treated. All quarters that cultured gram positive organisms were treated similar to the control group. All treated animals were tested and showed negative for milk antibiotic residue screening tests before their milk was allowed into the bulk tank for commercial purposes. Aseptic quarter milk samples of all animals were tested again at approximately fourteen and twenty-eight days postcalving to evaluate infection dynamics, spontaneous cures, treatment success, and new infections. Any cows with quarters showing clinical mastitis were not used for this portion of the study. Clinical Mastitis Protocol: Animals that developed clinical mastitis at any point during lactation (including at calving) were used in this trial. Clinical mastitis cows were identified by the milkers, and flagged for later evaluations. A CMT was performed and aseptic milk samples were taken from all CMT positive and/or clinical quarters. Samples were cultured similarly to the Fresh Cow Study. Mastitis cases were graded as follows: Grade 1 visual abnormalities in milk only; Grade 2 local gland abnormalities along with milk abnormalities; and Grade 3 systemic signs or abnormalities in addition to milk and udder abnormalities. All grade 3 mastitis cases were treated symptomatically based on treatment protocols and recommendations of the ISU herd veterinarian, and were not included in the study. Quarters with Grade 1 or 2 mastitis were randomly assigned to one of two treatment groups. Quarters in the control group were treated immediately following initial evaluation using the appropriate antimicrobial (see fresh cow protocol). Quarters in the second wait group were not treated until culture results were available twenty-four hours post evaluation, with the treatment regime being similar to the fresh cow protocol. See figure 2. Other bacteriological analysis and data capture were similar to the fresh cow group. CMT and culture data at calving was analyzed using a chi-square procedure. Sensitivity, specificity, positive predictive value, and negative predictive values were generated for the CMT at calving as well. Cure rates for

each group were also determined, along with new infection rate. A cure was considered to be achieved when a quarter that was culture positive at calving was culture negative upon subsequent testing fourteen days later. Likewise a new infection was defined as a quarter that had been culture negative at the previous test was now culture positive. Costbenefit analysis was also performed for each group. Costs for therapy included antimicrobials, labor, and milk discard. The cost of culturing an animal was determined using labor and material costs. Results Results for the fresh cow trial are shown in Tables 1-3. Table 1 shows a summary of fresh animals and infection status by sample dates. A total of 66 animals that calved had complete data (46 cows, 20 heifers) with 28.3 and 70% of animals, and 8.9 and 34.2% of quarters infected at calving in cows and heifers, respectively. Predominant organism in both groups was CNS and infection percentages were reduced into lactation as a result of therapy as well as spontaneous cure. CMT sensitivity, specificity, and predictive values (PPV and NPV) for cows and heifers for each sample date are shown in table 2. Overall sensitivity and PPV were low for both cows and heifers indicating the CMT made not be very good at identifying truly infected animals. Both high specificity and, especially, NPV substantiate that the CMT is an excellent tool to identify non-infected quarters and animals. Results were reasonably similar between heifers and cows, but heifers seemed to have a stronger CMT reaction when infected with CNS as compared to cows. Treatment results for the fresh cow trial are shown in table 3. Overall, a high percentage of CMT positive quarters were culture negative, resulting in a high percentage of uninfected control quarters being treated. Cure rates for treated infected quarters did not different between control and wait group, or heifer and cow groups. Results for the clinical mastitis trial are shown in tables 4-5. Table 4 shows a summary of clinical mastitis animals and infection status by sample dates. Most clinical mastitis was associated with environmental pathogens (streps. and gram negatives) or no growth. Clinical mastitis treatment results are shown in table 5. Over 50% of clinical cases showed no growth and resulted in a high percentage of these being treated in the control group. There were no differences in cure rates between groups. A partial budget with costs and assumptions for both the fresh cow and clinical mastitis trials is shown in Table 6. Costs associated with treating fresh cows were similar between control (treat immediately) and wait (24 hour, culture) groups. Although the control group treated more uninfected cows, the wait group incurred milk discard costs as the 24 hour lag resulted in dumping saleable milk. ing 24 hours to treat and culturing resulted in much lower overall costs compared to treat immediately for clinical mastitis cows, primarily as a result of the high percentage of clinical cows that were culture negative. Cure rates in both the fresh and clinical animals did not change when treatment was delayed for twenty-four hours while waiting for culture results (tables 3 and 5). This would indicate that waiting for culture results before instituting treatment does not affect treatment success. The on-farm culture system, in conjunction with the CMT, dramatically reduced the number of animals treated with antimicrobials as compared to basing treatment decisions off of the CMT or clinical symptoms only. In fresh animals the cost of waiting to treat animals and treating animals immediately was nearly equal. Although fewer animals were treated in the wait group, the cost of culturing and additional dump milk off-set the savings from treating fewer animals. However, this could change greatly based on labor and milk price and this does not take into account a reduction in potential antimicrobial residue risks. In clinical animals there was immense savings in culturing animals and only treating those necessary. Clinical situations that do not occur at calving are different than fresh cow mastitis because the amount of milk dumped during treatment is significantly greater, and the amount of milk dumped is the same regardless of when treatment is instituted. Since this is the case, spending a relatively small amount of money to perform a culture can result in larger savings because fewer animals are treated. The difference in the number of animals treated is enough that the reduced dump milk far offsets the cost of the culture.

Figure 1. Fresh cow CMT, culture, and treatment protocols. All Fresh Cows CMT Negative CMT and culture all quarters within 24 hours of calving CMT Positive No Treatment Random assignment to one of two treatment groups Group (W) Group (C) No growth or Gram (-) 24 hours for culture results Gram (+) Treat quarter(s) with Pirsue for two treatments 24 hours apart. 1 No Treatment Treat quarter(s) with Pirsue for two treatments 24 hours apart. 1 If Pirsue does not work after two days, or if susceptibility results show the organism is resistant to Pirsue, the antibiotic will be switched. -All animals will be rechecked at 14 & 28 days post-calving.

Figure 2. Clinical mastitis CMT, culture, and treatment protocols. All cows with clinical mastitis* Group (C) CMT and culture quarters. Cows divided into two groups. Group (W) Treat quarter(s) with Pirsue for two treatments 24 hours apart. 24 hours for culture results. Gram (-) or No Growth Gram (+) No treatment - Monitor The quarter(s) will be treated with Pirsue for two treatments, 24 hours apart. * All cows with clinical mastitis will be evaluated systemically via rumen movement and temperature. Any cows with Grade III mastitis will be treated accordingly and not used as part of the study. 1 If Pirsue does not work after two days, or if susceptibility results show the organism is resistant to Pirsue, the antibiotic will be switched. -All animals will be rechecked at 14 & 28 days post presentation. Table 1. Summary of fresh animals and infection status by sample dates. Summary of Fresh Animal Infections by Sample Calving 2 Weeks Post-Calving 4 Weeks Post-Calving Cows Heifers Cows Heifers Cows Heifers Number of Animals 46 20 44 20 37 16 % Animals Infected 28.3% 70% 25.0% 55.0% 19% 43.8% Number of Quarters 180 79 171 79 140 62 Number (%) of Quarters Infected Coagulase Negative Staphylococcus sp. Coagulase Positive Staphylococcus sp. 19 (8.9) 27 (34.2) 12 (7.0) 17 (21.5) 7 (5.0) 11 (17.7) 9 19 9 14 4 10 2 0 1 0 1 0 Streptococcus sp. 6 6 1 0 1 0 Other Gram Positives 0 1 1 1 1 1 Gram Negative Species 2 1 0 2 0 0

Table 2. CMT sensitivity, specificity, and predictive values (PPV and NPV) for cows and heifers for each sample date. Sensitivity & Specificity of Fresh Cow CMT Sensitivity Specificity PPV NPV Calving Day 63 1 (90 2 )% 93(93)% 52(45)% 96(99)% 14 Days Post-Calve 50(67)% 95(95)% 43(20)% 94(99)% 28 Days Post-Calve 86(100)% 95(95)% 46(30)% 99(100)% Sensitivity & Specificity of Fresh Heifer CMT Sensitivity Specificity PPV NPV Calving Day 52(88)% 81(81)% 58(41)% 77(98)% 14 Days Post-Calve 35(67)% 95(95)% 67(40)% 86(98)% 28 Days Post-Calve 36(0)% 92(92)% 50(0)% 87(98)% 1 all pathogens considered. 2 all pathogens with the exception of CNS. Table 3. Treatment results for the fresh cow trial. Treatment Results of Fresh Animal Infections (Tx d) 1 Cows w/ Tx 2 No Tx 3 (Tx d) Heifers w/ Tx Number of Animals 8 3 5 5 1 5 Number of Quarters 13 4 6 8 3 10 Culture Negative Quarters 5-6 4 - - 7 Quarters w/ CNS 1 1 1 5-2 CNS Quarters Cured 1 1 1 2-1 Quarters w/ CPS 2 - - - - - CPS Quarters Cured - - - - - - Quarters w/ Strep. sp. 4 1-3 3 - Strep. sp. Quarters Cured 4 1-3 3 - Quarters w/ Gram Negative 1-1 5 - - 1 Gram Negative Organisms Cured No Tx 1-1 5 - - 1 1 (Tx d) indicates animals in the control group - all CMT positive quarters were treated. 2 w/ Tx indicates animals that were in the wait 24 hours group, and received treatement. 3 No Tx indicates animals that were in wait 24 hr group, were culture negative, and did not receive treatment. 4 One of these quarters was inadvertently treated, however, it should not have been. 5 This animal was also inadvertently treated, her quarter cultured a gram negative organism, and it is was assumed that she would have cleared it on her own like the other without treatment.

Table 4. Summary of clinical mastitis animals and infection status by sample dates. Summary of Clinical Infections by Sample Initial Clinical Presentation 2 Weeks Post- Presentation 4 Weeks Post- Presentation Cows Heifers Cows Heifers Cows Heifers Number of Animals 11 7 10 7 11 6 Number of Quarters 43 28 38 28 41 23 Number (%) Clinical Mastitis Quarters Number (%) of Quarters Infected Coagulase Negative Staphylococcus sp. Coagulase Positive Staphylococcus sp. 19 (44.2) 7 (16.3) 11 (39.3) 7 (25.0) - - - - 7 (18.4) 8 (28.6) 6 (14.6) 5 (21.7) 4 1 4 5 6 3 0 0 0 0 0 0 Streptococcus sp. 1 4 3 2 0 0 Other Gram Positives 0 0 0 0 0 0 Gram Negatives 2 2 1 1 0 2 Table 5. Clinical mastitis treatment results. Treatment Results of Clinical Animal Infections (Tx d) Cows w/ Tx No Tx (Tx d) Heifers w/ Tx Number of Animals 7 1 3 5 2 - Number of Quarters 11 2 4 8 3 - Culture Negative Quarters 6 2 4 4 1 - Quarters w/ CNS 2 - - 1 - - CNS Quarters Cured 1 - - 1 - - Quarters w/ CPS - - - - - - CPS Quarters Cured - - - - - - Quarters w/ Streps sp. 3 - - 2 2 - Streps sp. Quarters Cured 2 - - 2 1 - Quarters w/ Gram egative - - - 1 - - Gram NegativesCured - - - 1 - - 1 There are more control than wait animals because several wait group cows could not finish the study for various reasons. No Tx

Table 6. Partial budgets with costs and assumptions for both the fresh cow and clinical mastitis trials. Partial Budget for & Groups Fresh Fresh Clinical Clinical CMT 1.00 1.00 - - Culture 1-3.75-3.75 Antimicrobial 2 9.50 3 8.00 4 8.00 5 7.50 6 Additional Dump Milk 7-7.50 30.00 30.00 Total per Animal 10.50 20.25 38.00 41.25 Total Cost per 100 Animals $199.50 8 $202.50 9 $285.00 10 $99.00 11 1 Cultures were assumed to be done in the parlor during milking time. Labor was assumed to be $10.00/hr, with a culture taking 10 minutes of total time. The rest of the cost is materials. 2 The antimicrobial was two tubes of Pirsue, which cost $5.00. 3 In the fresh groups, on average, each treated animal had 1.9CMT (+) quarters (1.8x5). 4 In the fresh wait group, on average, each infected animal had 1.6 infected quarters (1.6x5). 5 In the clinical control group, on average, each treated animal had 1.6 clinical quarters (1.6x5). 6 In the clinical wait group, on average, each infected animal had 1.5 infected quarters (1.5x5). 7 Milk from all fresh animals is dumped for the first six milkings, only milk dumped beyond that was considered in the cost. For fresh cows, daily production was assumed to be 50 lbs/day, with milk being dumped for one extra day. For clinical cows, daily production was assumed to be the herd average of 80 lbs/day, with 2.5 days of milk being dumped. Milk was assumed to be $15/cwt. 8 According to this studies results, 9% of quarters were CMT positive at calving, therefore, 400 quarters * 9% * 1/1.9 cow/quarters = ~19 animals treated. 9 According to this study s results, only 5% of quarters were bacteriologically positive, therefore, 400 quarters * 5% * 1/1.6 cow/quarters = ~10 animals treated. 10 Approximately 3% of the herd showed clinical mastitis all of which were treated in the control group, therefore, 400 quarters *3% *1/1.6 cow/quarter = 7.5 animals. 11 Approximately 3% of the herd showed clinical mastitis but only ~30% were bacteriologically positive, therefore, 400 quarters * 3% * 30% * 1/1.5 cow/quarters = 2.4 animals